Comment
Author: Admin | 2025-04-28
Diastolic responses 50–95% and 60–90%, respectively.Addition of a low dose of hydrochlorothiazide (12.5 mg) to losartan 50 mg once daily resulted in placebo-adjusted blood pressure reductions of 15.5/9.2 mmHg.Trial analysis of age, gender, and race subgroups of patients showed that men and women, and those over and under 65, had generally similar responses.Cozaar was effective in reducing blood pressure regardless of race, although the effect was somewhat less in Black patients (usually a low-renin population).Pediatric HypertensionThe efficacy of losartan was studied in one trial (n=177) involving hypertensive pediatric patients aged 6 to 16 years old. Children who weighed The sitting diastolic blood pressure (SiDBP) on entry into the study was higher than the 95th percentile level for the patient's age, gender, and height.At the end of 3 weeks, losartan reduced systolic and diastolic blood pressure, measured at trough, in a dose-dependent manner.Overall, the two higher doses (25–50 mg in patients The lowest dose, corresponding to an average daily dose of 0.07 mg/kg, did not appear to offer consistent antihypertensive efficacy.When patients were randomly assigned to continue losartan at the two higher doses or to placebo after 3 weeks of therapy, trough diastolic blood pressure rose in patients on placebo between 5 and 7 mmHg more than those who were randomly assigned to continue losartan.When the low dose of losartan was randomly withdrawn, the rise in trough diastolic blood pressure was the same in patients receiving placebo and in those continuing losartan, again suggesting that the lowest dose did not have significant antihypertensive efficacy.Overall, no significant differences in the overall antihypertensive effect of losartan were detected when the patients were analyzed according to age (Hypertensive Patients with Left Ventricular HypertrophyThe LIFE study (n=9193) was a multinational, double-blind trial comparing Cozaar vs atenolol in hypertensive patients with ECG-documented left ventricular hypertrophy. Patients with myocardial infarction or stroke within 6 months prior to randomization were excluded.Patients were randomly assigned to receive once daily Cozaar 50 mg or atenolol 50 mg. If goal blood pressure (If necessary, other antihypertensive treatments (eg, increase in dose of HCTZ therapy to 25 mg or addition of other diuretic therapy, calcium-channel blockers, alpha-blockers, or centrally acting agents, except ACE inhibitors, angiotensin II antagonists, or beta-blockers) were added to the treatment regimen to achieve blood pressure goal.The mean duration of follow-up was 4.8 years.The primary endpoint was the first occurrence of cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction.Patients with nonfatal events remained in the trial, so that there was also an examination of the first event of each type even if it was not the first event (eg, a stroke following an initial myocardial infarction would be counted in the analysis of stroke).Treatment with Cozaar resulted in a 13% reduction (P =0.021) in risk of the primary endpoint vs the atenolol group; this difference was primarily the result of an effect on fatal and nonfatal stroke.Treatment with Cozaar reduced the risk of stroke by 25% relative to atenolol (P =0.001).Although the LIFE study favored Cozaar over atenolol with
Add Comment